Retour
55
23
Fourchette du Jour
9,42 €
9,59 €
Fourchette 52 Semaines
9,23 €
16,00 €
Volume
4 258
Moyenne 50J / 200J
10,93 €
/
11,40 €
Clôture Précédente
9,27 €
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Healthcare (626 pairs)
| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | 0,2 | 0,4 |
| P/B | 0,0 | 2,9 |
| ROE % | 7,8 | 3,8 |
| Net Margin % | 6,3 | 3,9 |
| Rev Growth 5Y % | 3,1 | 10,0 |
| D/E | 0,2 | 0,2 |
Objectif de Cours des Analystes
Aucune couverture d'analyste disponible
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
0,00 €
0,00 € – 0,00 €
|
230 B | 0 |
| FY2026 |
0,00 €
0,00 € – 0,00 €
|
230 B | 0 |
Points Clés
Revenue grew 3,07% annually over 5 years — modest growth
Earnings declined -17,20% over the past year
Debt/Equity of 0,15 — conservative balance sheet
Generating 6,58B in free cash flow
P/E of 0,22 — trading at a low valuation
Capital efficient — spends only 3,86% of revenue on capex
Croissance
Revenue Growth (5Y)
3,07%
Revenue (1Y)1,55%
Earnings (1Y)-17,20%
FCF Growth (3Y)N/A
Qualité
Return on Equity
7,82%
ROIC7,55%
Net Margin6,25%
Op. Margin9,19%
Sécurité
Debt / Equity
0,15
Current Ratio2,53
Interest Coverage143,84
Valorisation
P/E Ratio
0,22
P/B Ratio0,02
EV/EBITDA0,04
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 1,55% | Revenue Growth (3Y) | 4,46% |
| Earnings Growth (1Y) | -17,20% | Earnings Growth (3Y) | -9,23% |
| Revenue Growth (5Y) | 3,07% | Earnings Growth (5Y) | -6,24% |
| Profitability | |||
| Revenue (TTM) | 225,42B | Net Income (TTM) | 14,10B |
| ROE | 7,82% | ROA | 5,46% |
| Gross Margin | 51,97% | Operating Margin | 9,19% |
| Net Margin | 6,25% | Free Cash Flow (TTM) | 6,58B |
| ROIC | 7,55% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,15 | Current Ratio | 2,53 |
| Interest Coverage | 143,84 | Dividend Yield | 0,01% |
| Valuation | |||
| P/E Ratio | 0,22 | P/B Ratio | 0,02 |
| P/S Ratio | 0,01 | PEG Ratio | -2,82 |
| EV/EBITDA | 0,04 | Dividend Yield | 0,01% |
| Market Cap | 3,09B | Enterprise Value | 739,91M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 225,42B | 221,99B | 206,60B | 205,13B | 199,73B |
| Net Income | 14,10B | 17,03B | 17,11B | 23,44B | 18,24B |
| EPS (Diluted) | 42,44 | 50,61 | 50,82 | 69,13 | 53,56 |
| Gross Profit | 117,16B | 111,35B | 103,27B | 106,73B | 100,05B |
| Operating Income | 20,71B | 19,59B | 21,12B | 30,99B | 27,10B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 258,28B | 233,23B | 216,73B | 210,20B | 193,03B |
| Total Liabilities | 76,98B | 52,15B | 49,12B | 53,82B | 54,04B |
| Shareholders' Equity | 179,55B | 181,08B | 167,60B | 156,38B | 138,99B |
| Total Debt | 26,08B | 654,00M | 441,00M | 359,00M | 404,00M |
| Cash & Equivalents | 28,43B | 36,13B | 43,99B | 60,10B | 44,36B |
| Current Assets | 183,09B | 184,33B | 172,50B | 171,88B | 156,14B |
| Current Liabilities | 72,30B | 49,90B | 46,57B | 50,80B | 50,61B |
Scores de Stratégies
This stock passed the criteria for 2 strategies
Score = fit strength (0–100)
Rank = position among all matches
#216 of 820
#425 of 708
Activité Récente
Entré
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Entré
Defensive Investing (Benjamin Graham)
Mar 24, 2026